Percheron Therapeutics (ASX:PER) has announced final results from its Phase I clinical trial of HMBD-002, a novel immunotherapy targeting multiple forms of advanced cancer, showing a strong safety profile and early signs of clinical activity. …
Percheron Therapeutics reports positive final data from early-phase trial of HMBD-002
October 7, 2025 Australian Biotech
Latest Video
New Stories
-
Australians want better access to medical technology, and a clearer pathway to get there
October 28, 2025 - -
Pharmacy Guild backs expanded prescribing rights for optometrists
October 28, 2025 - - Latest News -
PYC reports strong clinical momentum and cash position ahead of key readouts
October 27, 2025 - - Australian Biotech -
Government backs new national push to close bone health testing gap for women
October 27, 2025 - - Latest News -
Leadership change at PolyNovo as long-time Chair steps down
October 27, 2025 - - Australian Biotech -
Cann Group announces major debt restructure and capital raise to strengthen balance sheet
October 27, 2025 - - Australian Biotech -
FDA awards the first-ever national priority vouchers to nine sponsors
October 27, 2025 - - Latest News